• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

December 31, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the below information following the issuance on 8 December 2021 of 6,500,000 new shares of Celyad Oncology SA (the “Company”) to an affiliate of Fortress Investment Group (such affiliate “Fortress”). As a result, the Company’s share capital has been increased to 78,584,224.33 EUR and is represented by 22,593,956 shares.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures – Modified on 8 December 2021 following the capital Increase:

Total amount of share capital (EUR)78,584,224.33
Total Number of shares with single voting rights20,225,931
Total Number of shares with double voting rights2,368,025
Total Number of Shares22,593,956
Total of voting rights24,961,981
Total number of attributed warrants1,997,190
Total number of shares with voting rights that could be created following the exercise of the attributed warrants1,997,190
Total number of diluted shares (Outstanding shares + Warrants)24,591,146
Total number of diluted shares with voting rights26,959,171

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

Further questions about the content of this release can be sent to investors@celyad.com.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy